- Home
- STRO vs KPTI Comparison
STRO vs KPTI Comparison
Compare STRO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- KPTI
- Stock Information
- Founded
- STRO 2003
- KPTI 2008
- Country
- STRO United States
- KPTI United States
- Employees
- STRO N/A
- KPTI N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- KPTI Health Care
- Exchange
- STRO Nasdaq
- KPTI Nasdaq
- Market Cap
- STRO 94.9M
- KPTI 102.4M
- IPO Year
- STRO 2018
- KPTI 2013
- Fundamental
- Price
- STRO $0.89
- KPTI $5.62
- Analyst Decision
- STRO Hold
- KPTI Strong Buy
- Analyst Count
- STRO 7
- KPTI 6
- Target Price
- STRO $1.97
- KPTI $22.17
- AVG Volume (30 Days)
- STRO 782.2K
- KPTI 111.5K
- Earning Date
- STRO 11-06-2025
- KPTI 11-03-2025
- Dividend Yield
- STRO N/A
- KPTI N/A
- EPS Growth
- STRO N/A
- KPTI N/A
- EPS
- STRO N/A
- KPTI N/A
- Revenue
- STRO $105,646,000.00
- KPTI $142,530,000.00
- Revenue This Year
- STRO $65.48
- KPTI $4.87
- Revenue Next Year
- STRO N/A
- KPTI $9.20
- P/E Ratio
- STRO N/A
- KPTI N/A
- Revenue Growth
- STRO N/A
- KPTI N/A
- 52 Week Low
- STRO $0.52
- KPTI $3.51
- 52 Week High
- STRO $3.01
- KPTI $13.20
- Technical
- Relative Strength Index (RSI)
- STRO 48.24
- KPTI 45.34
- Support Level
- STRO $0.81
- KPTI $5.31
- Resistance Level
- STRO $0.95
- KPTI $6.50
- Average True Range (ATR)
- STRO 0.08
- KPTI 0.41
- MACD
- STRO -0.00
- KPTI 0.00
- Stochastic Oscillator
- STRO 53.02
- KPTI 36.25
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.